Krystal Biotech (KRYS) stock
Follow KRYS's trial news. Pro members can get an alert when Krystal Biotech files news, and see its trials, share raises, and its CEO's filings.
What's next for KRYS
From Krystal Biotech’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Dilution on the horizon
No shelf registration of its own or at-the-market program on file in the last three years.
Insiders
President, R&D Suma Krishnan sold 25,000 shares on Sep 4, under a planned sale. 13 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 28 daysINOInovio Pharmaceuticals
INOINO-3107
- In 39 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 51 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why KRYS scores 8
AverageChoppy, 2 of 14 checks firingWhat the Quality Score means
- +2Chart checks 2 of 14 firing right now, one point each
- +2Long-term trend above a rising 200-day average
- Profit adds
- Growth adds
- Persistence adds
- Insider trades subtracts
What's next
Expected to report Mon Nov 2, before the open
After its last 3 reports it closed -1.4% on average, higher 2 of 3 times.
What would move KRYS's score: 5 things, for Pro members
Here is what Pro members see.
Every stock has a live page like this, KRYS included: the price in real time, the full chart, all 14 checks, and every line of its score.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
KRYS has 2 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1436.6
- MACD (12, 26, 9)Below signal
- 50-day average$342.43
- 200-day average$301.37
- ADX 1413.6
- Support$297.02
- Resistance$353.84
- Volume1.5x
How KRYS ranks in Biotech
KRYS is #47 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
EXEL7/1417
AMRX6/1417
KODOpen for its score
KURAOpen for its score
KYMROpen for its score
KRYS2/148
When does KRYS report earnings, and what happens after?
Expected to report Mon Nov 2, before the open (in 31 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 3, 2026Before open | Before open | -6.0% | -8.4% | -4.3% |
| Feb 17, 2026Before open | Before open | +4.5% | +4.1% | -0.7% |
| Nov 3, 2025Before open | Before open | +0.1% | +0.2% | +0.2% |
Who is trading KRYS
KRYS insider trades
One insider sold $8.2M across 8 filings in the last 6 months. No open-market buys on record. The newest:
KRYS trades by Congress and the White House
2 trades disclosed in the last six months. The newest:
About Krystal Biotech
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of KRYS's score, with the points and the reason
- All 14 checks on KRYS and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on KRYS
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.